Chronic cerebrovascular diseases and neuroprotection: the clinical efficacy of meldonium (Mildronat)
Authors:
- 1 January 2020
- journal article
- research article
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 120 (10) , 14-21
Abstract
To evaluate the efficacy of meldonium (mildronat) in patients with chronic cerebral vascular disease (CVD). An open comparative study of the clinical efficacy of meldonium (mildronat) in patients with chronic CVD caused by arterial hypertension and atherosclerosis was conducted. The main group included 30 (60%) patients who were prescribed meldonium (mildronat) at a dose of 1000 mg per day in addition to routine basic therapy. The control group was consisted of 20 (40%) patients who received routine basic therapy only. The duration of the study was 60 days. To evaluate the clinical efficacy of the meldonium (mildronat), the main subjective clinical symptoms, neurological, psychoemotional and cognitive status, quality of life were assessed when patients were included in the study (before treatment), on the 11th and 60th days from the start of treatment. To assess the meldonium (mildronat) effect on the endothelium vascular wall, asymmetric dimethylarginine (ADMA), tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) and endothelin-1 were determined in the blood when patients were included in the study, on the 11th and 60th days from the start of treatment. Meldonium (mildronat) has a positive therapeutic effect on the main clinical symptoms and cognitive functions which appears in increasing the quickness of mental activity, improving short-term and operative memory, increasing the resistance of mental processes and memory traces to interfering influences, and improving cognitive evoked potentials P300 results. Meldonium (mildronat) therapy leads to the decrease in the level of state and trait anxiety. The quality of life of patients treated with meldonium (mildronat) increases due to the physical and mental components. The effect of meldonium (mildronat) on the decrease in endothelin-1 and PAI-1 levels, which indicates the antitrombogenic effect of the drug, has been identified. Nootropic, anxiolytic and antitrombogenic effects of meldonium (mildronat) in patients with chronic CVD are demonstrated that makes it possible to recommend this drug for widespread use by specialists in clinical practice.Keywords
This publication has 19 references indexed in Scilit:
- Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegenerationThe Lancet Neurology, 2013
- Role of the vascular endothelium and plaque in acute ischemic strokeNeurology, 2012
- Endothelial dysfunction : the early predictor of atherosclerosisCardioVascular Journal of Africa, 2012
- Endothelial Activation in Lacunar Stroke SubtypesStroke, 2010
- NO synthase: Structures and mechanismsNitric Oxide, 2010
- Neuroprotection for ischemic stroke: Past, present and futureNeuropharmacology, 2008
- The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive ImpairmentJournal of the American Geriatrics Society, 2005
- Endothelial functionThe American Journal of Cardiology, 2002
- “Mini-mental state”Journal of Psychiatric Research, 1975
- A Self-Rating Depression ScaleArchives of General Psychiatry, 1965